Thrombocytopenia as an adverse effect of levetiracetam therapy in a child

Neuropediatrics. 2009 Oct;40(5):243-4. doi: 10.1055/s-0030-1247524. Epub 2010 Mar 10.

Abstract

Levetiracetam is one of the newer anti-epileptic medications, which is now widely used in the treatment of childhood epilepsy. Thrombocytopenia is not a well-known adverse effect of this medication. There have only been two adult case reports describing this feature as an adverse effect of levetiracetam. We describe this feature in a child. A six and half-year-old boy developed symptomatic epilepsy secondary to cerebral venous sinus thrombosis. He was treated with levetiracetam. He made a good recovery from his primary illness, but five weeks after he started taking levetiracetam, he presented with thrombocytopenia requiring platelet transfusion. Extensive investigations for known causes of thrombocytopenia were negative. Withdrawal of levetiracetam led to the resolution of thrombocytopenia. Levetiracetam-induced thrombocytopenia is a rare, but significant adverse effect.

Publication types

  • Case Reports

MeSH terms

  • Anticonvulsants / adverse effects*
  • Anticonvulsants / therapeutic use*
  • Child
  • Epilepsy / drug therapy
  • Epilepsy / etiology
  • Humans
  • Levetiracetam
  • Male
  • Piracetam / adverse effects
  • Piracetam / analogs & derivatives*
  • Piracetam / therapeutic use
  • Sinus Thrombosis, Intracranial / complications
  • Thrombocytopenia / chemically induced*

Substances

  • Anticonvulsants
  • Levetiracetam
  • Piracetam